107 related articles for article (PubMed ID: 3305224)
1. Neuraminidase-treated allogeneic blasts for maintenance in acute myelogenous leukemia: results of a prospective randomized trial.
Urbanitz D; Büchner T; Pielken H; Koch P; Ludwig WD; Maschmeier G; Heinecke A; van de Loo J
Haematol Blood Transfus; 1987; 30():64-8. PubMed ID: 3305224
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy with allogeneic neuraminidase-treated blasts for maintenance in acute myelogenous leukemia (AML). Significant prolongation of remission duration in patients receiving at least 3 cycles of therapy.
Urbanitz D; Pielken HJ; Koch P; Büchner T; Hiddemann W; Heinecke A; Wendt F; Maschmeier G; van de Loo J
Onkologie; 1985 Jun; 8(3):157-9. PubMed ID: 3895098
[TBL] [Abstract][Full Text] [Related]
3. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Büchner T; Hiddemann W; Wörmann B; Löffler H; Gassmann W; Haferlach T; Fonatsch C; Haase D; Schoch C; Hossfeld D; Lengfelder E; Aul C; Heyll A; Maschmeyer G; Ludwig WD; Sauerland MC; Heinecke A
Blood; 1999 Jun; 93(12):4116-24. PubMed ID: 10361108
[TBL] [Abstract][Full Text] [Related]
4. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
Büchner T; Urbanitz D; Hiddemann W; Rühl H; Ludwig WD; Fischer J; Aul HC; Vaupel HA; Kuse R; Zeile G
J Clin Oncol; 1985 Dec; 3(12):1583-9. PubMed ID: 3906048
[TBL] [Abstract][Full Text] [Related]
5. A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC.
Hayat M; Jehn U; Willemze R; Haanen C; Zittoun R; Monconduit M; Lowenberg B; Stryckmans P; Peetermans M; De Cataldo F
Cancer; 1986 Aug; 58(3):617-23. PubMed ID: 3524789
[TBL] [Abstract][Full Text] [Related]
6. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
7. A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.
Vogler WR; Winton EF; Gordon DS; Raney MR; Go B; Meyer L
Blood; 1984 May; 63(5):1039-45. PubMed ID: 6201211
[TBL] [Abstract][Full Text] [Related]
8. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group.
Amadori S; Testi AM; Aricò M; Comelli A; Giuliano M; Madon E; Masera G; Rondelli R; Zanesco L; Mandelli F
J Clin Oncol; 1993 Jun; 11(6):1046-54. PubMed ID: 8501490
[TBL] [Abstract][Full Text] [Related]
9. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.
Stein RS; Vogler WR; Winton EF; Cohen HJ; Raney MR; Bartolucci A
Leuk Res; 1990; 14(10):895-903. PubMed ID: 2259226
[TBL] [Abstract][Full Text] [Related]
10. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial.
Rees JK; Gray RG; Swirsky D; Hayhoe FG
Lancet; 1986 Nov; 2(8518):1236-41. PubMed ID: 2878130
[TBL] [Abstract][Full Text] [Related]
11. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
Jehn U; Heinemann V
Haematol Blood Transfus; 1990; 33():333-8. PubMed ID: 1691134
[TBL] [Abstract][Full Text] [Related]
12. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
[TBL] [Abstract][Full Text] [Related]
13. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
[TBL] [Abstract][Full Text] [Related]
15. Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy.
Omura GA; Vogler WR; Lefante J; Silberman H; Knospe W; Gordon D; Jarrell R
Cancer; 1982 Apr; 49(8):1530-6. PubMed ID: 7039813
[TBL] [Abstract][Full Text] [Related]
16. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
Archimbaud E; Fiere D; Treille-Ritouet D; Adeleine P; Guyotat D; Sebban C; Vuvan H; Viala JJ
Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788
[TBL] [Abstract][Full Text] [Related]
17. [Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
Hübner G; Link H; Schönrock-Nabulsi P; Wandt H; Gramatzki M; Löffler B; Fackler-Schwalbe I; Queisser W; Brack N; Geer T; Raab M; Ohl S; Schneider B; Schneider C; Freund M; Poliwoda H; Ehninger G
Med Klin (Munich); 1996 Apr; 91 Suppl 3():26-32. PubMed ID: 8692115
[TBL] [Abstract][Full Text] [Related]
18. Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
Linkesch W; Michlmayr G; Gerhartz H; Illinger H; König H; Düllmann J; Keilhauer R; Moldrzyk D
Onkologie; 1989 Feb; 12(1):8-10. PubMed ID: 2654791
[TBL] [Abstract][Full Text] [Related]
19. High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial.
Heil G; Mitrou PS; Hoelzer D; Freund M; Link H; Ehninger G; Steinke B; Ohl S; Wandt H; Fackler-Schwalbe E
Ann Hematol; 1995 Nov; 71(5):219-25. PubMed ID: 7492624
[TBL] [Abstract][Full Text] [Related]
20. A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
Jehn U; Zittoun R; Suciu S; Fiere D; Haanen C; Peetermans M; Löwenberg B; Willemze R; Solbu G; Stryckmans P
Haematol Blood Transfus; 1990; 33():277-84. PubMed ID: 1691132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
